Table 1 Baseline Characteristics
Variable | Pharmacist-counseled n = 100 | Standard of care n = 100 | P-value |
|---|---|---|---|
Sex | 0.669 | ||
Male | 46 | 43 | |
Female | 54 | 57 | |
Age (Mean in years, +/− SD) | 74.69 +/− 12.09 | 73.15+/− 14.74 | 0.420 |
Weight (Mean in Kg, +/− SD) | 75.52 +/− 18.39 | 73.60 +/− 17.83 | 0.465 |
Smoker | 27 | 26 | 1.000 |
Allergic to one or more drugs | 22 | 14 | 0.141 |
Creatinine clearance closest to the date of prescribing | 0.541 | ||
< 15 mL/min | 2 | 1 | |
15 - < 30 mL/min | 5 | 10 | |
30 - 50 mL/min | 21 | 19 | |
> 50 mL/min | 51 | 61 | |
Insurance type | 0.072 | ||
Private | 37 | 23 | |
Public | 37 | 39 | |
None (self) | 26 | 5 | |
Indication for anticoagulation | 0.236 | ||
Atrial fibrillation | 79 | 70 | |
VTE treatment | 8 | 11 | |
Aortic valve replacement | 7 | 11 | |
Mitral valve replacement | 4 | 7 | |
Antiplatelet use upon admission | 0.431 | ||
Aspirin 80–100 mg | 17 | 19 | |
Aspiring 162–325 mg | 2 | 0 | |
Clopidogrel 75 mg | 5 | 3 | |
Dual antiplatelet | 1 | 4 | |
Anticoagulant prescribed upon discharge | 0.006 | ||
Vitamin K antagonist | 33 | 53 | |
DOAC | 67 | 47 | |
DOAC prescribed upon discharge | |||
Apixaban | 15 | 3 | 0.005 |
Dabigatran | 12 | 15 | 0.535 |
Rivaroxaban | 40 | 29 | 0.102 |
HAS-BLED risk score (Mean +/− SD) | 2.26 +/− 1.3 | 2.23 +/− 1.05 | 0.882 |
Past medical history | |||
Hypertension | 71 | 68 | 0.645 |
Heart failure | 34 | 20 | 0.026 |
Chronic kidney disease | 13 | 12 | 0.831 |
Cancer | 13 | 15 | 0.684 |
History of bleeding | 8 | 5 | 0.390 |
History of gastrointestinal bleeding | 6 | 4 | 0.516 |